Microsoft has partnered with and invested in US-based Adaptive Biotechnologies to map the human immune system genetics using artificial intelligence (AI) for early detection and diagnosis of multiple diseases, including cancer.
Mevion S250i is a compact proton therapy system that has the capacity to deliver conformal radiation therapy treatments with the support of Hyperscan pencil beam scanning technology.
BioNTech has raised $270 million (€224 million). The series A round positions the German biotech to mount a multifront attack on cancer, spearheaded by mRNA therapies and supported by a clutch of other modalities including CAR-T cells.
Sangamo Therapeutics Inc and Pfizer Inc said on Wednesday they would work together to develop a gene therapy to treat ALS
Scholar Rock has raised $47 million to take its treatment for spinal muscular atrophy (SMA) into the clinic. The series C tees up Scholar Rock to find out whether its myostatin blocker can best the underwhelming performance of one-time rivals from companies including Novartis.
Recent innovations from global device makers like Abbott to smaller specialists such as Nevro Corp. made the implants more powerful and effective. Combined with a national crackdown on narcotics and wanton pain pill prescriptions, they are spurring demand for implants.
The first portable bionic hand restores the sense of touch in people who lost their limbs. Although the hand is still a prototype, we're one step closer to the day when a fully natural, sensorized prosthesis will be available.
Analysts and investors think Perjeta’s end-of-the-year indication may not be as lucrative as they once hoped. The FDA green-lighted the drug in tandem with giant Herceptin and chemo for HER2-positive, post-surgery breast cancer patients with a high risk of recurrence. Patients should receive up to 18 cycles of the regimen over the course of one year, according to the indication.
Mallinckrodt, which has landed in hot water multiple times this year, is diversifying beyond its controversial lead seller.
Janssen has entered into a global collaboration and license agreement with Legend Biotech USA and Legend Biotech Ireland to develop, manufacture and commercialise experimental CART-cell therapy LCAR-B38M.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.